Publications by authors named "Todd Triplett"

Claim this Profile
S
SARS-CoV-2 humoral immune responses in convalescent individuals over 12 months reveal severity-dependent antibody dynamics.
Nadia Siles Alvarado, Maisey Schuler, Cole Maguire, Dzifa A Amengor, Annalee W Nguyen, Todd A Triplett

Commun Med (Lond)· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SARS-CoV-2 Humoral Immune Responses in Convalescent Individuals Over 12 Months Reveal Severity-Dependent Antibody Dynamics.
Nadia Siles, Maisey Schuler, Cole Maguire, Dzifa Amengor, Annalee Nguyen, Todd A Triplett

medRxiv· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-Human Dose-Escalation Study of the Novel Oral Depsipeptide Class I-Targeting HDAC Inhibitor Bocodepsin (OKI-179) in Patients with Advanced Solid Tumors.
Anna R Schreiber, Jodi A Kagihara, Bradley R Corr, S Lindsey Davis, Christopher Lieu, Todd A Triplett

Cancers (Basel)· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Elucidating the direct effects of the novel HDAC inhibitor bocodepsin (OKI-179) on T cells to rationally design regimens for combining with immunotherapy.
Nisha Holay, Alexander Somma, Mark Duchow, Milad Soleimani, Anna Capasso, Todd A Triplett

Front Immunol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Leveraging immune resistance archetypes in solid cancer to inform next-generation anticancer therapies.
Kristin G Anderson, David A Braun, Aitziber Buqué, Sarah B Gitto, Jennifer L Guerriero, Todd A Triplett

J Immunother Cancer· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Longitudinal COVID-19 immune trajectories in patients with neurological autoimmunity on anti-CD20 therapy.
Sam A Bazzi, Cole Maguire, Nisha Holay, Janelle Geltman, Kerin Hurley, Todd A Triplett

Mult Scler Relat Disord· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Covalent JNK Inhibitor, JNK-IN-8, Suppresses Tumor Growth in Triple-Negative Breast Cancer by Activating TFEB- and TFE3-Mediated Lysosome Biogenesis and Autophagy.
Milad Soleimani, Alexander Somma, Tamer Kaoud, Ria Goyal, Jorge Bustamante, Todd Triplett

Mol Cancer Ther· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Microglia depletion and alcohol: Transcriptome and behavioral profiles.
Anna S Warden, Todd A Triplett, Aram Lyu, Emily K Grantham, Moatasem M Azzam

Addict Biol· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Current methods in translational cancer research.
Michael W Lee, Mihailo Miljanic, Todd Triplett, Craig Ramirez, Kyaw L Aung

Cancer Metastasis Rev· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor-associated myeloid cells provide critical support for T-ALL.
Aram Lyu, Todd A Triplett, Seo Hee Nam, Zicheng Hu, Dhivya Arasappan

Blood· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-HER2 induced myeloid cell alterations correspond with increasing vascular maturation in a murine model of HER2+ breast cancer.
Meghan J Bloom, Angela M Jarrett, Todd A Triplett, Anum K Syed, Tessa Davis

BMC Cancer· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune Checkpoint Blockade in Gastrointestinal Cancers: The Current Status and Emerging Paradigms.
Mihailo Miljanic, Anna Capasso, Todd A Triplett, S Gail Eckhardt, Kyaw L Aung

J Immunother Precis Oncol· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reversal of indoleamine 2,3-dioxygenase-mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme.
Todd A Triplett, Kendra C Garrison, Nicholas Marshall, Moses Donkor, John Blazeck

Nat Biotechnol· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Endogenous dendritic cells from the tumor microenvironment support T-ALL growth via IGF1R activation.
Todd A Triplett, Kim T Cardenas, Jessica N Lancaster, Zicheng Hu, Hilary J Selden

Proc Natl Acad Sci U S A· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
STAT3 Signaling Is Required for Optimal Regression of Large Established Tumors in Mice Treated with Anti-OX40 and TGFβ Receptor Blockade.
Todd A Triplett, Christopher G Tucker, Kendra C Triplett, Zefora Alderman, Lihong Sun

Cancer Immunol Res· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual anti-OX40/IL-2 therapy augments tumor immunotherapy via IL-2R-mediated regulation of OX40 expression.
William L Redmond, Todd Triplett, Kevin Floyd, Andrew D Weinberg

PLoS One· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Defining a functionally distinct subset of human memory CD4+ T cells that are CD25POS and FOXP3NEG.
Todd A Triplett, Brendan D Curti, Peter R Bonafede, William L Miller, Edwin B Walker

Eur J Immunol· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis